Cardiometabolic & kidneyMeta-analysis
Effects of Canagliflozin on Total Heart Failure Events Across the Kidney Function Spectrum: Participant-Level Pooled Analysis from the CANVAS Program and CREDENCE Trial
- Pooled participant-level analysis of the CANVAS Program and CREDENCE randomised trials
- blinded adjudication of heart failure (HF) hospitalizations
Authors' conclusion
In individuals with T2D at high cardiovascular risk and/or with chronic kidney disease, canagliflozin reduced the total burden of HF hospitalizations, with consistent benefits observed across the kidney function spectrum.
Study context
- Population
- T2D at high CV risk and/or with CKD, by baseline estimated glomerular filtration rate (eGFR) (<45, 45–60, >60 ml/min/1.73 m²)with baseline eGFR
- Participants
- 14,540 participants
- Comparison
- Canagliflozin vs placebo
- Outcome
- Total (first and recurrent) HF hospitalizations by baseline kidney function
- Follow-up
- Median 2.5 years
Pooled result
Total HF hospitalizations
Mean event ratio
0.63
95% CI 0.54–0.73
As reported in the abstract
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| First HF hospitalization | 0.58 (0.48–0.70) | |
| 0.512Hazard ratio (log scale) |
events
| Outcome | Canagliflozin | Placebo | mean event ratio (95% CI) |
|---|---|---|---|
| CV death and total HF hospitalizations | 0.72 (0.65–0.80) | ||
| Single HF hospitalization | 156 | 201 |
- First HF hospitalization: interaction P = 0.84
- CV death and total HF hospitalizations: interaction P = 0.82
Absolute benefit by kidney function
- Larger absolute benefits in participants with worse baseline kidney function
Original publication
Effects of Canagliflozin on Total Heart Failure Events Across the Kidney Function Spectrum: Participant-Level Pooled Analysis from the CANVAS Program and CREDENCE Trial. Eur J Heart Fail. Published 26 June 2024. doi:10.1002/ejhf.3292
Summarised from the published abstract; every number is checked against it